Cyprotex PLC Launch of Solution to Predict Preclinical Toxicity
November 18 2015 - 04:16AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
17 November 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Launch of New Solution to Predict Preclinical Toxicity
17(th) November 2015;
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the launch of its new in silico
modelling solution, chemTox, which predicts genotoxicity and rat
LD(50) directly from chemical structure. The LD(50) is a commonly
determined parameter in preclinical toxicity studies, representing
the dose that causes death in 50% of the test group. Using models
such as those in chemTox to predict this parameter will have
obvious ethical benefits in reducing animal toxicity testing.
chemTox has been developed by Cyprotex's Scientific Computing
Group using quantitative structure property relationship (QSPR)
modelling, a technique that relates calculable chemical
characteristics of a molecule to important properties such as its
toxicity. As chemTox requires no experimental data inputs it can be
used as a virtual screening tool prior to chemical synthesis. There
are significant cost benefits to this approach as chemTox can be
applied as an early stage filter for directing chemistry and
prioritising subsequent in vitro screening by taking into account
the predicted safety of the molecule. Cyprotex not only provide the
in silico predictions but can provide a full tiered screening
strategy with safety of the molecules substantiated using a panel
of in vitro toxicity assays.
By utilising chemTox alongside complementary virtual screening
tools such as chemPK(TM) , which was launched by Cyprotex in July,
it is possible to predict both preclinical safety and human
exposure in combination. Both systems operate on a similar KNIME
workflow management platform which allows further integration with
many other cheminformatics, analytics and modelling tools.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments:
'The ethical concerns over animal testing are intensifying and new
approaches which reduce or in the future replace animal safety
testing are a key focus. Virtual screening tools such as chemTox
address this need, and are becoming widely used in industries such
as cosmetics and personal care where a complete ban on animal
testing has been enforced.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1300 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions, including Cloe(R) PK, chemPK(TM)
and chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKADNPBDDDDD
(END) Dow Jones Newswires
November 17, 2015 02:01 ET (07:01 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2023 to Mar 2024